Upadacitinib Demonstrates Continued Improvements in Patients With Moderate to Severe AD Through 140 Weeks
Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.
Ritlecitinib Shows Promising Results in Long-Term Trial
Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.
Considerations for Topical Therapeutics and Clinical Excellence in Vitiligo
Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.
Serum CXCL10 Levels Decreased With Use of Ruxolitinib Cream In Patients With Vitiligo
Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.
A RAVE Upgrade: Previewing Revolutionizing Alopecia Areata, Vitiligo, and Eczema
Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.
Spotlighting Vitiligo: New Innovations to be Presented at RAVE 2024
Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.
What to Expect at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
The inaugural RAVE conference begins today in Chicago, Illinois.
Career Insights: Advocating and Negotiating for PAs
Renata Block, MMS, PA-C, discusses contracts, work environments, and more with SDPA presenter and past president Gina Mangin, MPAS, PA-C.
Advances in HS: Insights and Interventions Shared at Annual Conference
Jennifer Hsiao, MD, shares insights on emerging therapies and comprehensive care strategies at the 2024 SDPA Annual Summer Dermatology Conference.
Opening Doors of Communication: Social Media Trends and Challenges
Luke Maxfield, DO, discusses the importance of understanding social media trends and engaging patients in dialogues.
This or That at SDPA Summer Dermatology Conference: Sunscreens
What's the preferred sunscreen and why? Renata Block, MMS, PA-C, talks to the attendees of the 2024 SDPA Annual Summer Dermatology Conference.
A Conversation With Amber Blair, MMS, PA-C, at the SDPA Conference
The SDPA President Elect shared insights, hopes for the field, and the importance of leadership.
SDPA Literature Review Session Shares Clinical Pearls
This special literature review yields a deeper understanding of issues like treating acne, nutraceuticals, and more.
A Positive Outlook With Laura Bush, DMSc, PA-C, DFAAPA
Laura Bush, DMSc, PA-C, DFAAPA, talks to Renata Block, MMS, PA-C, about her SDPA presidency, the future, and the importance of a positive outlook.
Quality of Life Improved in GPP in Effisayil 2 Trial
Poster presented at the SDPA conference reported Effisayil 2 data indicating spesolimab improved Dermatology Life Quality Index scores in patients with generalized pustular psoriasis.
Journey of Philanthropy and Leadership
Renata Block, MMS, PA-C, and Faseeha Raza, PA-C, discuss the DPAF, philanthropy, leadership, and the importance of patient care.
Getting JAK’d With Amy Spizuoco, DO, FAOCD
The JAK inhibitors have demonstrated efficacy, yet some clinicians are still wary of prescribing them. Amy Spizuoco, DO, FAOCD, shares tips to help clinicians improve their comfort in using them.
An Evolving Field: A Conversation With Renata Block, MMS, PA-C
What are some of the opportunities and challenges facing PAs today? Renata Block, MMS, PA-C, shares insights and reflections on the field.
Brodalumab Performs in Phase 4 Studies of Moderate to Severe Psoriasis
The results indicated improvement in PASI and sPGA scores as well as improvement in quality of life indicators in adults with moderate to severe psoriasis.
SDPA Poster Reports Positive Phase 3 Results of Dupilumab for PN
Researchers found dupilumab improved itch and skin lesions regardless of atopic disease status in patients with PN.
